Correlation Between KABE Group and Hansa Biopharma

Can any of the company-specific risk be diversified away by investing in both KABE Group and Hansa Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining KABE Group and Hansa Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between KABE Group AB and Hansa Biopharma AB, you can compare the effects of market volatilities on KABE Group and Hansa Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in KABE Group with a short position of Hansa Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of KABE Group and Hansa Biopharma.

Diversification Opportunities for KABE Group and Hansa Biopharma

0.57

Correlation Coefficient

KABE Group  Hansa Biopharma

Very weak diversification

The 3 months correlation between KABE and Hansa is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding KABE Group AB and Hansa Biopharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hansa Biopharma AB and KABE Group is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on KABE Group AB are associated (or correlated) with Hansa Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hansa Biopharma AB has no effect on the direction of KABE Group i.e., KABE Group and Hansa Biopharma go up and down completely randomly.

Pair Corralation between KABE Group and Hansa Biopharma

Assuming the 90 days trading horizon KABE Group AB is expected to generate 0.49 times more return on investment than Hansa Biopharma. However, KABE Group AB is 2.02 times less risky than Hansa Biopharma. It trades about -0.06 of its potential returns per unit of risk. Hansa Biopharma AB is currently generating about -0.18 per unit of risk. If you would invest  32,092  in KABE Group AB on September 3, 2024 and sell it today you would lose (2,192) from holding KABE Group AB or give up 6.83% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

KABE Group AB  vs.  Hansa Biopharma AB

KABE Group AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days KABE Group AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong fundamental drivers, KABE Group is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

Hansa Biopharma AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Hansa Biopharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with KABE Group and Hansa Biopharma

The main advantage of trading using opposite KABE Group and Hansa Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if KABE Group position performs unexpectedly, Hansa Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hansa Biopharma will offset losses from the drop in Hansa Biopharma's long position.

The idea behind KABE Group AB and Hansa Biopharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .